A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-Containing and cyclosporin A-Free immunosuppressive regimens

Clinical Therapeutics

Volumn 28, Issue 6, 2006, Pages 893-905

  Dösch, Andreas O ^a   Ehlermann, Philipp ^a   Koch, Achim ^b   Remppis, Andrew ^a   Katus, Hugo A ^a   Dengler, Thomas J ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

area under the curve; cyclosporin A; drug monitoring; limited sampling strategies; mycophenolic acid; rapamycin; sirolimus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DIET RESTRICTION; DISEASE SEVERITY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FATIGUE; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HEART GRAFT; HEART TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; LEUKOPENIA; MALE; PATIENT CARE; POSTOPERATIVE COMPLICATION; PREDICTION; RECIPIENT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VALIDATION PROCESS; VALIDATION STUDY; VENOUS BLOOD;

AREA UNDER CURVE; CYCLOSPORINE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS;

EID: 33745944728     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.06.015     Document Type: Article

References (25)

1. Allison A.C., and Eugui E.M. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 14 (1993) 353-380
2. Eugui E.M., Almquist S.J., Muller C.D., and Allison A.C. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scand J Immunol 33 (1991) 161-173
3. van Gelder T., Klupp J., Barten M.J., et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23 (2001) 119-128
4. Yatscoff R.W., and Aspeslet L.J. The monitoring of immunosuppressive drugs: A pharmacodynamic approach. Ther Drug Monit 20 (1998) 459-463
5. Bullingham R.E., Nicholls A.J., and Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34 (1998) 429-455
6. Cattaneo D., Merlini S., Zenoni S., et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 5 (2005) 2937-2944
7. Bullingham R.E., Nicholls A., and Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): A short review. Transplant Proc 28 (1996) 925-929
8. Weber L.T., Shipkova M., Armstrong V.W., et al. The pharmacokineticpharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13 (2002) 759-768
9. van Gelder T., Le Meur Y.L., Shaw L.M., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28 (2006) 145-154
10. [published correction appears in Ther Drug Monit. 2000;22:500]. Oellerich M., Shipkova M., Schütz E., et al., German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring. Ther Drug Monit 22 (2000) 20-26
11. Le Guellec C., Buchler M., Giraudeau B., et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol 57 (2002) 805-811
12. Schütz E., Armstrong V.W., Shipkova M., et al., German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. Transplant Proc 30 (1998) 1182-1184
13. Vogl M., Weigel G., Seebacher G., et al. Evaluation of the EMIT Mycophenolic Acid Assay from Dade Behring. Ther Drug Monit 21 (1999) 638-643
14. Hosotsubo H., Takahara S., Imamura R., et al. Analytic validation of the enzyme multiplied immunoassay technique for the determination of mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatographic assay. Ther Drug Monit 23 (2001) 669-674
15. Weber L.T., Shipkova M., Armstrong V.W., et al. Comparison of the Emit immunoassaywith HPLCfortherapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 48 (2002) 517-525
16. Shaw L.M., Nicholls A., Hale M., et al. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 31 (1998) 317-322
17. Pawinski T., Hale M., Korecka M., et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 48 (2002) 1497-1504
18. Weber L.T., Schütz E., Lamersdorf T., et al., German Study Group on Mycophenolate Mofetil (MMF) Therapy. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPAAUC in paediatric renal transplant recipients. Nephrol Dial Transplant 14 Suppl 4 (1999) 34-35
19. Abstract. Schütz E., Armstrong V.W., Weber L., et al. MPA-AUC models in relation to outcome in pediatric Ktx. Ther Drug Monit 21 (1999) 479
20. Angermann C.E., Stork S., Costard-Jackle A., et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients-the IMPROVED multi-centre study. Eur Heart J 25 (2004) 1626-1634
21. Kobashigawa J., Miller L., Renlund D., et al., Mycophenolate Mofetil Investigators. A randomized active controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66 (1998) 507-515
22. Borrows R., Chusney G., Loucaidou M., et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: Association with acute rejection and toxicity. Am J Transplant 6 (2006) 121-128
23. Shaw L.M., Korecka M., Venkataramanan R., et al. Mycophenolic acid pharmacodynamics and pharmaco kinetics provide a basis for rational monitoring strategies. Am J Transplant 3 (2003) 534-542
24. Meiser B.M., Pfeiffer M., Schmidt D., et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 18 (1999) 143-149
25. Beal J.L., Jones C.E., Taylor P.J., and Tett S.E. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. Ther Drug Monit 20 (1998) 685-690